Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Italy / NCT07847463
Recruiting Observational

Can Exercise Electrocardiography Discriminate Hypertensive Heart Disease From Obstructive Coronary Artery Disease? A Multimodality Imaging Study

NCT07847463 · tracked via the Priya Life Science Italy tracker
Sponsor
University of Pisa
Phase
Observational
Started
2026-09-01
Last updated
2026-09-29

Condition(s) studied

Obstructive Coronary Artery DiseaseLeft Ventricular Hypertrophy

Study summary

To evaluate the ability of exercise ECG to discriminate between hypertensive heart disease-related and CAD-related abnormalities

Eligibility

Sex
ALL
Min age
18 Years
Max age
99 Years
Healthy volunteers
No
Inclusion Criteria: * Patients with CAD and LVH Exclusion Criteria: * Patients with RBBB

Primary outcome measure(s)

  • diagnostic performance of exercise ECG across the four predefined groups. — From enrollment through completion of all diagnostic evaluations, assessed up to 3 months after enrollment.
    Differences in ECG response patterns will be compared according to the presence of LVH and obstructive CAD. Multivariable analysis will be performed to identify independent ECG predictors associated with obstructive CAD and inducible ischemia.

Trial sites (1)

FacilityCityRegionStatus
Azienda Ospedaliero-Universitaria Pisana Pisa PI Recruiting

More University of Pisa trials in Italy

Pharmacokinetics of Intravenous Acyclovir in Oncologic Paediatric Patients Recruiting
Clinical Outcomes of Immediate Implants With or Without a Volume-stable Collagen Matrix Active, not recruiting
Application of Ultra-high Frequency Ultrasonography (UHFUS) to the Study of Gingival Tissues Recruiting
Retinal OCTA for Microvascular Dysfunction Evaluation and Outcome Prediction in MINOCA Patients Recruiting
Evaluation of a Multimodal Tactile Feedback System for Upper Limb-loss Users: Embodiment and Performance Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07847463 on ClinicalTrials.gov ↗ ← All trials in Italy